A new deep-learning system called Atomic Rotationally Equivariant Scorer (ARES) significantly improves the prediction of RNA structures over previous artificial intelligence (AI) models.
Stanford researchers have discovered that amphipathic α-helical (AH) peptides that share an amino acid sequence homology to the N-terminus of HCV NS5A can rupture lipid vesicles in a size-dependent manner.
Stanford researchers have identified several peptides that inhibit the binding between certain nonstructural proteins of hepatitis C virus and cytoplasmic membranes.
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Researchers in Prof. Stephen Quake's laboratory have developed a CRISPER-Cas-based targeted endonuclease system designed to treat latent viral infections by attacking the viral genome.
The standard treatment for hepatitis C virus (HCV) is poorly tolerated and ineffective in a large subset of HCV patients. Scientists at Stanford and UCSF have developed new therapeutic leads for HCV that also have potential to be broad-spectrum anti-infectives.
Researchers in Prof. Mark Kay's laboratory have developed recombinant adeno-associated viral (AAV) capsid proteins that transduce human primary hepatocytes at high efficiency in vitro and in vivo.